Current Therapeutic Strategies of Intervertebral Disc Regenerative Medicine

被引:0
作者
Elmounedi, Najah [1 ]
Bahloul, Walid [1 ,2 ]
Keskes, Hassib [1 ,2 ]
机构
[1] Sfax Fac Med, Cell Therapy & Expt Surg Musculoskeletal Syst LR18, Majida Boulila Rd, Sfax 3029, Tunisia
[2] CHU Habib Bourguiba, Dept Orthoped & Traumatol, Sfax, Tunisia
关键词
NUCLEUS PULPOSUS CELLS; MESENCHYMAL STEM-CELLS; PLATELET-RICH PLASMA; LOW-BACK-PAIN; TISSUE-GROWTH-FACTOR; BONE MORPHOGENETIC PROTEIN-2; ANNULUS FIBROSUS CELLS; VERTEBRAL END-PLATE; IN-VIVO; EXTRACELLULAR-MATRIX;
D O I
10.1007/s40291-024-00729-7
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Intervertebral disc degeneration (IDD) is one of the most frequent causes of low back pain. No treatment is currently available to delay the progression of IDD. Conservative treatment or surgical interventions is only used to target the symptoms of IDD rather than treat the underlying cause. Currently, numerous potential therapeutic strategies are available, including molecular therapy, gene therapy, and cell therapy. However, the hostile environment of degenerated discs is a major problem that has hindered the clinical applicability of such approaches. In this regard, the design of drugs using alternative delivery systems (macro-, micro-, and nano-sized particles) may resolve this problem. These can protect and deliver biomolecules along with helping to improve the therapeutic effect of drugs via concentrating, protecting, and prolonging their presence in the degenerated disc. This review summarizes the research progress of diagnosis and the current options for treating IDD.
引用
收藏
页码:745 / 775
页数:30
相关论文
共 278 条
[1]   Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β [J].
Abreu, JG ;
Ketpura, NI ;
Reversade, B ;
De Robertis, EM .
NATURE CELL BIOLOGY, 2002, 4 (08) :599-604
[2]   Neural crest stem cells: discovery, properties and potential for therapy [J].
Achilleos, Annita ;
Trainor, Paul A. .
CELL RESEARCH, 2012, 22 (02) :288-304
[3]   Healing of a painful intervertebral disc should not be confused with reversing disc degeneration: Implications for physical therapies for discogenic back pain [J].
Adams, Michael A. ;
Stefanakis, Manos ;
Dolan, Patricia .
CLINICAL BIOMECHANICS, 2010, 25 (10) :961-971
[4]   Transplantation of human Wharton's jelly-derived mesenchymal stem cells highly expressing TGFβ receptors in a rabbit model of disc degeneration [J].
Ahn, Jongchan ;
Park, Eun-mi ;
Kim, Byeong Ju ;
Kim, Jin-Soo ;
Choi, Bogyu ;
Lee, Soo-Hong ;
Han, Inbo .
STEM CELL RESEARCH & THERAPY, 2015, 6
[5]   ACUTE MECHANICAL INJURY OF THE HUMAN INTERVERTEBRAL DISC: LINK TO DEGENERATION AND PAIN [J].
Alkhatib, B. ;
Rosenzweig, D. H. ;
Krock, E. ;
Roughley, P. J. ;
Beckman, L. ;
Steffen, T. ;
Weber, M. H. ;
Ouellet, J. A. ;
Haglund, L. .
EUROPEAN CELLS & MATERIALS, 2014, 28 :98-111
[6]   Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: a prospective randomized, placebo-controlled 36-month study of safety and efficacy [J].
Amirdelfan, Kasra ;
Bae, Hyun ;
McJunkin, Tory ;
DePalma, Michael ;
Kim, Kee ;
Beckworth, William J. ;
Ghiselli, Gary ;
Bainbridge, James Scott ;
Dryer, Randall ;
Deer, Timothy R. ;
Brown, Roger D. .
SPINE JOURNAL, 2021, 21 (02) :212-230
[7]   Mesenchymal stem cells: immune evasive, not immune privileged [J].
Ankrum, James A. ;
Ong, Joon Faii ;
Karp, Jeffrey M. .
NATURE BIOTECHNOLOGY, 2014, 32 (03) :252-260
[8]  
[Anonymous], ClinicalTrials.gov
[9]  
[Anonymous], ClinicalTrials.gov
[10]  
[Anonymous], 2021, EudraCT identifier no. 2019-002749-40